

| | Total respondents (n=30) | CAB members (n=24) | Industry representatives (n=6) |
|---|--------------------------|--------------------|--------------------------------|
| To ensure products better meet patients' unmet medical needs | 1 | 1 | 1 |
| To make clinical trials more patient-oriented and reduce the burden of trial participation | 2 | 4 | 3 |
| To broaden access to products (in clinical trials and after market approval) and diminish access inequalities | 3 | 2 | 5 |
| To improve efficiency and speed of health product R&D | 4 | 3 | 6 |
| To enhance transparency and trust between the patient community and the pharmaceutical industry | 5 | 5 | 2 |
| To make patients more respected partners throughout the health product life cycle | 6 | 6 | 4 |
| To empower CAB members and the patient community through knowledge-sharing | 7 | 7 | 7 |





